Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

2010 Company Financials: Orthopaedic and Spine

The following summarizes publicly available year over year earnings results to date. Our estimates place year over year market growth at 5% thus far, as indicated in Exhibit 1, which displays growth by product segment. Performance highlights relate to 2010, unless otherwise noted.

Exhibit 1: Orthopaedic Sales1 Increases by Product Segment: 2010 vs. 2009


1Orthopaedic products only; constant currency, pro forma growth
2For the quarter ended 11/30/10; excludes dental; trauma includes stimulators; spine includes stimulators and orthobiologics.
3ORTHOWORLD estimates

Biomet (for fiscal 2Q11, ended 11/30/10)

$698.3MM, +2%

  • U.S. $416.9MM, +2%
  • Europe $188.8MM, -1%
  • International $92.6MM, +7%

Reconstructive $540.5MM, +3% (U.S. +3%)

  • Hips flat (U.S. flat)
  • Knees +3% (U.S. +3%)
  • Extremities +23% (U.S. +36%)
  • Other -3% (U.S. -2%)

Fixation $56.3MM, -2% (U.S. -1%)

Spine $56.0MM, -3% (U.S. flat)

Other $45.5MM, +2% (U.S. +2%)

  • Sports Medicine +17% (U.S. +17%)
  • Other -14% (U.S. -16%)

Overall growth includes Dental.

  • Not observing a lot of movement in larger U.S. hospital customers toward purchasing to eliminate the distributor and manage inventory on their own